Heard on the Street: Moderna's mRNA cancer vaccine marks a major leap in personalized oncology. But the financial math is sobering.

Personalized mRNA shots may prove neither as wide-reaching nor as lucrative as hoped.

WSJ • 3 hours ago

Moderna Stock Is Just The Start: Why AI-Focused Money Might Flow Into Biotech

Moderna stock could catch the eye of investors looking for the next big AI play, Revere Asset Management's Don Vandenbord says.

Investors Business Daily • Aug 21, 2026

Moderna's 177% Surge Has Investors Asking What Comes Next

It's not every day that a company already worth billions sees its shares nearly triple in a single trading session. Welcome to the world of biotech, because that's exactly what happened to Moderna Inc. NASDAQ: MRNA on Wednesday of this week, after the Massachusetts-based company stunned the market with a breakthrough that sent its stock rocketing to a multi-year high.

MarketBeat • Aug 21, 2026

Moderna Soars 129% for the Week | Closing Bell

Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Sally Bakewell, Carol Massar and Emily Graffeo. -------- More on Bloomberg Television and Markets Like this video?

Bloomberg Markets and Finance • Aug 21, 2026

If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now

Shares of Moderna Inc (NASDAQ:MRNA) had their best day in history as a public company this week, with the stock soaring on positive news from a Phase 3 trial with Merck & Co (NYSE:MRK). The news was a major win for investors in the stock who have seen pressure on financials and shares since the end of the COVID-19 pandemic.

Benzinga • Aug 21, 2026

Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session

The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single trial readout with no fresh clinical information hitting the tape Friday.

24/7 Wall Street • Aug 21, 2026

How a Big Bet on Cancer Vaccines Brought Moderna Back from the Brink

After years of layoffs, cash burn and political attacks on its core technology, Moderna's melanoma vaccine data notched the biotech company a much-needed win.

WSJ • Aug 22, 2026

Stock Market Rally Buckles; Moderna, Gold, Bitcoin Surge While Walmart Tumbles: Weekly Review

The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped.

Investors Business Daily • Aug 21, 2026

COVID-19 Made Moderna Famous: Cancer Could Define Its Future

For years, Moderna, Inc‘s (NASDAQ:MRNA) biggest challenge wasn't developing new medicines — it was convincing investors that it could thrive after COVID-19. The company's vaccine transformed it into one of the world's most recognizable biotech names, but as the pandemic demand faded, so did its revenue and stock price.

Benzinga • Aug 21, 2026

MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week

Retail investors talked up five hot stocks during the week (Aug. 17 to Aug. 21) on X and Reddit's r/WallStreetBets, driven by retail hype, earnings, AI infrastructure momentum, and corporate news flow.

Benzinga • Aug 21, 2026